|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
Besides, p16 methylation was not linked to clinical stage, prostate-specific antigen (PSA) level, and Gleason score (GS) of patients with PCa. p14 methylation was not correlated with PCa in tissue and urine samples.
|
29561434 |
2018 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
Malignant neoplasm of prostate
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
Inverse association of p16 INK4a and p14 ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer.
|
21912429 |
2011 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
We and others previously reported that p14 alternative reading frame (ARF) expression is positively correlated with the disease progression and severity of PCa.
|
23449888 |
2013 |
|
Malignant neoplasm of breast
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases.
|
18245468 |
2008 |
|
Malignant neoplasm of breast
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
In addition, DAPK, hMLH1, and p14 genes promoter hypermethylation were significantly associated with the susceptibility of breast cancer.
|
30572486 |
2018 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
p14 expression seems to increase initially in early breast cancer and decrease with further tumour progression. p14 may be induced to counteract immortalisation and hTERT surge.
|
23645774 |
2013 |
|
Malignant neoplasm of breast
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was; 1) To explore alterations in the TP53 gene with respect to resistance to a regular dose epirubicin regimen (90 mg/m(2) every 3 week) in patients with primary, locally advanced breast cancer; 2) Identify critical mechanisms activating p53 in response to DNA damage in breast cancer; 3) Evaluate in vitro function of Chk2 and p14 proteins corresponding to identified mutations in the CHEK2 and p14((ARF)) genes; and 4) Explore potential CHEK2 or p14((ARF)) germline mutations with respect to family cancer incidence.
|
18725978 |
2008 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
There was a significant correlation between the presence of MMTV (identified by p14 immunohistochemistry) in human breast cancers and histological characteristics similar to MMTV positive mouse mammary tumors (<i>p</i> = 0.001).
|
29868468 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Identification of MMTV-associated p14 proteins in benign breast tissues confirms prior PCR-based studies that MMTV infection occurs before the development of MMTV positive breast cancer.
|
29868468 |
2018 |
|
Breast Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases.
|
18245468 |
2008 |
|
Breast Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was; 1) To explore alterations in the TP53 gene with respect to resistance to a regular dose epirubicin regimen (90 mg/m(2) every 3 week) in patients with primary, locally advanced breast cancer; 2) Identify critical mechanisms activating p53 in response to DNA damage in breast cancer; 3) Evaluate in vitro function of Chk2 and p14 proteins corresponding to identified mutations in the CHEK2 and p14((ARF)) genes; and 4) Explore potential CHEK2 or p14((ARF)) germline mutations with respect to family cancer incidence.
|
18725978 |
2008 |
|
Breast Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
In addition, DAPK, hMLH1, and p14 genes promoter hypermethylation were significantly associated with the susceptibility of breast cancer.
|
30572486 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
p14 expression seems to increase initially in early breast cancer and decrease with further tumour progression. p14 may be induced to counteract immortalisation and hTERT surge.
|
23645774 |
2013 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The methylation frequencies of the ten genes examined in HCC were 40.0% for p14 ( ARF ), 60.9% for p15 ( INK4b ), 70.4% for p16 ( INK4a ), 34.8% for p73, 70.4% for GSTP1, 64.3% for MGMT, 13.0% for hMLH1, 59.1% for RARbeta, 82.6% for SOCS-1, and 80.9% for OPCML.
|
20112070 |
2010 |
|
Liver carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the risk of HCC is related to P14 methylation, but not MGMT methylation.
|
25169493 |
2014 |
|
Liver carcinoma
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
In Australian HCC the prevalence of p14 methylation increased with age (P = 0.03). p16 promoter methylation was observed in 12/37 (32%) and 6/24 (25%) in Australian and South African HCC, respectively.
|
11982701 |
2002 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
HBV infection is associated with p14 (ARF) , p15 (INK4B) , p16 (INK4A) , and RB gene methylation (P = 0.048, 0.035, 0.02); HBV-DNA replication is associated with p14 (ARF) , p15 (INK4B) , p16 (INK4A) , and RB gene methylation (P = 0.048, 0.035, 0.02); high rate of p14 (ARF) , p15 (INK4B) , and p16 (INK4A) in HCC with HBV infection suggests that HBV-induced hypermethylation may be one of the mechanisms of HBV involved in hepatocellular carcinogenesis.
|
24254306 |
2014 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The status of p14 was evaluated in 117 HCC tumoral nodules and 110 corresponding non-tumor tissues by loss of heterozygosity at the 9p21-22 region, homozygous deletions, single strand conformation polymorphism-polymerase chain reaction mutational analysis and methylation-specific polymerase chain reaction.
|
15095848 |
2004 |
|
Colorectal Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We have determined the presence of mutations in the K-ras gene and the methylation status of p16 promoter in a series of 119 prospectively collected colorectal carcinomas. p53 mutations and p14 alternative reading frame methylation status were also assessed.
|
11208819 |
2001 |
|
Colorectal Carcinoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant promoter methylation of p16 and p14 genes was detected in 43 of 86 (50%) and 25 of 86 (29%) colorectal cancers, respectively.
|
12716465 |
2002 |
|
Colorectal Carcinoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
A recent study has shown an inverse correlation between CIN and CIMP (determined by MINTs, p16, p14 and MLH1 methylation) in colorectal cancer.
|
17474983 |
2007 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We investigated the role of p14 in colorectal cancer by determining its methylation status in cancers that were studied previously for microsatellite instability, CIMP, and mutations of p53 and K-RAS.
|
12612901 |
2003 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Strong staining of p14 was found in 63% of nodular melanomas and was associated with strong p53 expression (p=0.014), and with high levels of CDK4 (p<0.0001).
|
15547691 |
2004 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARβ signaling.
|
23851445 |
2013 |